Takeda bids adieu to Uloric after gout med's gradual fade from glory

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S.

This week, the medicine, first approved in 2009, was listed as discontinued on the FDA’s online drug shortage database. The drug, also known as febuxostat, was cleared for chronic management of hyperuricemia—or high uric acid levels in the body—in patients with gout and was previously available in 40-mg and 80-mg tablets.